HOME >> BIOLOGY >> NEWS
Staph aureus bacteremia in ESRD patients associated with substantial illness and higher costs

Chicago, Illinois, September 17, 2003 Substantial treatment costs and illness are suffered by end-stage kidney (renal) disease (ESRD) patients who develop Staph aureus blood stream infections (bacteremias), according to new pharmacoeconomic studies presented this week at the 43rd annual Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) in Chicago, IL. Moreover, ESRD patients with Staph aureus bacteremia that are caused by bacteria that are resistant to the antibiotic methicillin (MRSA) are at a higher risk of dying and incur higher treatment costs than patients with bacteremias caused by methicillin sensitive Staph aureus (MSSA). The two studies, sponsored by Nabi Biopharmaceuticals, Inc. (Nasdaq: NABI) and executed by Duke University Medical Center, were presented by investigators from Duke University Medical Center and Duke Clinical Research Institute, Durham, NC.

"Staph aureus is the most common cause of serious hospital-acquired infections, including bloodstream infections, and their increased resistance to many different antibiotics is a growing source of concern in the medical community," said Henrik S. Rasmussen, M.D., Ph.D., Nabi Biopharmaceuticals senior vice president, clinical, medical and regulatory affairs. "Despite its clinical significance, the economic impact of Staph aureus bacteremia has not been fully appreciated. The two studies presented at ICAAC clearly describe the clinical outcomes, associated with health care resource utilization and infection-associated costs of Staph aureus bacteremia among a large group of prospectively identified, hemodialysis-dependent patients. The full data from these studies have been submitted for publication."

"Clearly, these studies point out the tremendous challenges that continue to face healthcare professionals trying to manage Staph aureus bacteremias in ESRD patients," continued Dr. Rasmussen. "These results underscore the need for a new approach such as Nabi Biopharmac
'"/>

Contact: Joan Kureczka
JKureczka@aol.com
415-821-2413
Kureczka/Martin Associates
17-Sep-2003


Page: 1 2 3 4 5

Related biology news :

1. An aspirin a day keeps Staphylococcus aureus away
2. Discovery of iron-acquisition pathway suggests new treatments for drug-resistant Staph. infections
3. The growing Staphylococcus aureus arsenal
4. Surprising role for Staphs toxic shock toxin
5. Nabi experimental vaccine reduced Staph aureus bloodstream infections by nearly 60 percent
6. Staph bacteria are prolific gene swappers, researchers show
7. Experimental Staph Vaccine Broadly Protective In Animal Studies
8. Nabi reports successful reduction in S. aureus bacteremias at Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC)
9. Trial shows which brain cancer patients benefit from temozolomide
10. Study of flu patients reveals virus outsmarting key drug
11. Decreasing toxins in brains of Alzheimers patients keep cognitive deficits at bay

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:5/11/2020)... (PRWEB) , ... May 11, 2020 , ... ... remote monitoring software platform for patients with implanted cardiac devices. The Octagos software ... using one portal. The software greatly simplifies the management of remote transmissions and ...
(Date:5/6/2020)... ... May 06, 2020 , ... ... Texas, http://www.brevitest.com ) will become the latest out-of-state company to partner ... Inner Harbor. , Brevitest has developed a point-of-care analyzer capable of accurately ...
(Date:5/1/2020)... ... April 30, 2020 , ... Flagship Biosciences ... Consulting Inc., a biopharmaceutical and regulatory services advisor. The companies now deliver regulatory ... and Corritori are taking a collaborative approach to empower more confident and informed ...
Breaking Biology News(10 mins):
(Date:5/14/2020)... ... May 12, 2020 , ... NanoString Technologies ... together thousands of industry leaders, clinicians, research scientists, medical professionals and academics from ... June, MD, Director of the Center for Cellular Immunotherapies at the Perelman School ...
(Date:5/5/2020)... (PRWEB) , ... May 05, 2020 , ... ProductLife ... a high-profile CEO. Xavier Duburcq joins the group after 13 years at Altran, where ... , Holding a PhD in Immunology and being a Pharmacist, Xavier was involved in ...
(Date:4/22/2020)... ... April 20, 2020 , ... Global molecular ... today that Omixon’s founder and chairman Dr. Attila Berces returns as CEO. Outgoing ... HLA since 2014 before stepping into the CEO role in 2017. , ...
(Date:4/7/2020)... ... 2020 , ... Red Nucleus, a leading provider of strategic ... release of at-home virtual learning resources for all client partners. , “With the ... our employees as we continue to implement measures to safeguard the well-being of ...
Breaking Biology Technology:
Cached News: